Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06576102
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-27
Brief Title:
Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluation of Prevalence and Risk Factors of Persistent SARS-CoV-2 Infection in Immunocompromised Patients
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PERsiCO
Brief Summary:
Spontaneous international multicenter retrospective and prospective observational study which objective is to evaluate the prevalence and risk factors of persistent SARS-CoV-2 infection within a population of hematology patients with humoral immunity deficiency
Detailed Description:
Spontaneous international multicenter retrospective and prospective observational study which objective is to evaluate the prevalence and risk factors of persistent SARS-CoV-2 infection within a population of hematology patients with humoral immunity deficiency
The retrospective recruitment period will span from January 1st 2022 to the date of authorisation by hospital directorates following the Ethics Committees approvals This period has been established considering the prevalent diffusion of the omicron variant and its subvariants which has led to significant changes in the clinical manifestations of COVID-19 The prospective recruitment will be carried out over the 12 months immediately following the retrospective period During the study period screening for persisting SARS-CoV-2 infection and therapeutic management of all patients will be carried out by the attending physicians according to routine practice
This study is enclosed in the EU Horizon 2020 project Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic ORCHESTRA Grant Agreement No 101016167 and is located within Task 46 Prevalence risk factors and therapeutic management of persistent COVID-19 in frail patients It is expected to enroll approximately 1000 patients 500 at the coordinating center
The retrospective recruitment period will span from January 1st 2022 to the date of authorisation by hospital directorates following the Ethics Committees approvals This period has been established considering the prevalent diffusion of the omicron variant and its subvariants which has led to significant changes in the clinical manifestations of COVID-19 The prospective recruitment will be carried out over the 12 months immediately following the retrospective period During the study period screening for persisting SARS-CoV-2 infection and therapeutic management of all patients will be carried out by the attending physicians according to routine practice
This study is enclosed in the EU Horizon 2020 project Connecting European Cohorts to Increase Common and Effective Response to SARS-CoV-2 Pandemic ORCHESTRA Grant Agreement No 101016167 and is located within Task 46 Prevalence risk factors and therapeutic management of persistent COVID-19 in frail patients It is expected to enroll approximately 1000 patients 500 at the coordinating center
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None